Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for mild to moderate COVID-19 in out-of-hospital care
jRCTs071220085Phase 2Active, not recruiting
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Colchicine with Placebo (2 arms). Primary endpoint: Number of fever-free days in 14 days. Started Jan 2023; status: active, not recruiting.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs071220085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220085.